CLAIMS

1. A liquid formulation comprising:
- melatonin in particulate solid form,
- a vehicle which is an oil, comprised in the liquid formulation in an amount of at least 80% w/v,
- a viscosity increasing agent.

2. The formulation according to claim 1, wherein the formulation is in the form of a suspension.

3. The formulation according to any one of the preceding claims, wherein the amount of melatonin is from 1 to 30 mg/mL, preferably from 2 to 20 mg/mL, more preferably from 3 to 15 mg/mL, even more preferably from 5 to 10 mg/mL.

4. The formulation according to any one of the preceding claims, wherein the vehicle which is an oil is selected from medium chain triglycerides and vegetable oils.

5. The formulation according to claim 4, wherein the vehicle which is an oil is medium chain triglycerides.

6. The formulation according to any one of the preceding claims, wherein the amount of oil comprised in the liquid formulation is expressed as at least 90% w/w.

7. The formulation according to any one of the preceding claims, wherein the viscosity increasing agent is selected from: colloidal silicon dioxide; a composition comprising at least 70% by weight of a mixture of mono-, di- and/or tri-glycerides, wherein said mono-, di- or tri-glycerides are selected from C_{16} to C_{22} fatty acid esters of glycerol; and xanthan gum.

8. The formulation according to any one of the preceding claims, wherein the viscosity increasing agent is colloidal silicon dioxide, and is comprised in the formulation in an amount of between 0.01 and 3% w/v, preferably between 0.05 and 1% w/v, more preferably between 0.1 and 0.5% w/v, even more preferably between 0.1 and 0.3% w/v, of the formulation.

9. The formulation according to any one of the preceding claims, wherein the viscosity increasing agent is a composition comprising at least 70% by weight of a mixture of

mono-, di- and/or tri-glycerides, wherein said mono-, di- or tri-glycerides are selected from C_{16} to C_{22} fatty acid esters of glycerol, and wherein said composition is present in the formulation in an amount of between 0.05 and 3% w/v, even more preferably between 0.1 and 1 % w/v, of the formulation.

10. The formulation according to any one of the preceding claims, wherein the viscosity increasing agent is a composition comprising at least 70% by weight of a mixture of mono- and di-glycerides, wherein said mono- and di-glycerides are C_{22} fatty acid esters of glycerol.

11. The formulation according to any one of claims 1 to 10, wherein the viscosity increasing agent is a composition comprising at least 70% by weight of a mixture of mono-, di- and tri-glycerides, wherein said mono-, di- and tri-glycerides are C_{16} and/or C_{18} fatty acid esters of glycerol.

12. The formulation according to claim 1, comprising:
- melatonin in particulate solid form, in an amount from 2 to 20 mg/mL, preferably from 3 to 15 mg/mL,
- medium chain triglycerides in an amount between 90 and 99 % w/v, preferably 91 and 97 % w/v,
- colloidal silicon dioxide in an amount between 0.1 and 0.5 % w/v, preferably 0.1 and 0.3 % w/v.

13. The formulation according to any one of the preceding claims, in a form suitable for oral administration by ingestion.

14. Method for preparing a formulation as defined in claims 1-to 13, said method comprising the following steps:
- Mixing the vehicle which is an oil in liquid form with the viscosity increasing agent in solid form;
- Adding the melatonin in particulate form into the mixture obtained in step a) and mixing.

15. Use of a formulation as defined in any of claims 1 to 13 in the manufacture of a medicament for the prevention and/or treatment of insomnia and circadian rhythm sleep-wake disorders.

16. The use according to claim 15, wherein the formulation is administered orally.